[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100400373":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Baylor Research Institute","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Shelley A Hall, MD FACC","BSWRI","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Joost Felius, PhD","CONTACT","214-818-8943","Joost.Felius@BSWHEALTH.ORG",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Baylor Scott & White Health Research Institute","RECRUITING","Dallas","Texas","75246","United States","US",{"type":29,"coordinates":30},"Point",[31,32],-96.80667,32.78306,{"lat":32,"lon":31},[35],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100400373","the-hepatitis-c-transplant-collaborative-100400373",false,"NCT04493385","The Hepatitis C Transplant Collaborative","Nationwide Hepatitis C NAT+ Cardiac Transplant Experience","Inclusion Criteria:\n\n1. Recipient of a proven HCV NAT+ donor heart.\n2. Re-transplant patients will be included.\n\nExclusion Criteria:\n\n1\\. Multi-organ transplantation",true,"ALL","18 Years",{"count":49,"type":50},500,"ESTIMATED","OBSERVATIONAL","In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.",[54,55],"Transplant; Failure, Heart","Hepatitis C","2026-01-20",{"date":58,"type":59},"2026-01-22","ACTUAL",{"date":61,"type":59},"2019-09-16",{"date":63,"type":50},"2030-12",{"name":5,"class":6},1]